Private Equity For The People: 3 High-Yield BDCs Yielding Up To 13%
Let's invest like private equity pros without needing seven figures. Yes, that's right—PE-style starting for as little as $8.
Crescent Capital: 11% Yield And Fire Sale Price Make It A Buy
Crescent Capital BDC offers a compelling 10.9% dividend yield and trades at a 22% discount to NAV, providing a strong margin of safety. Recent headwinds, including lower NII and some non-accruals, are largely priced in, with the portfolio remaining healthy and well-protected by first-lien debt. Management's confidence is evident through continued regular dividends and two special dividends, signaling belief in near-term NII recovery.
Crescent Capital BDC, Inc. (CCAP) Q1 2025 Earnings Conference Call Transcript
Crescent Capital BDC, Inc. (NASDAQ:CCAP ) Q1 2025 - Earnings Conference Call May 15, 2025 12:00 PM ET Company Participants Dan McMahon - Head, IR Jason Breaux - CEO Henry Chung - President Gerhard Lombard - CFO Conference Call Participants Paul Johnson - KBW Robert Dodd - Raymond James Finian O'Shea - Wells Fargo Mickey Schleien - Ladenburg Thalmann Operator Good morning, and welcome to Crescent Capital BDC, Inc. First Quarter Ended March 31, 2025 Earnings Conference Call. Please note that Crescent Capital BDC, Inc. may be referred to as CCAP, Crescent BDC or the company throughout the call.
Crescent Capital BDC (CCAP) Q1 Earnings and Revenues Lag Estimates
Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.63 per share a year ago.
I'm Buying 2 Income Machines With 5-12% Yields
Spring is an ideal time for income investors to revisit portfolios, focusing on quality stocks like Crescent Capital BDC and Federal Realty Trust. Crescent Capital BDC offers a 12.4% yield, strong dividend coverage, and a diversified, conservatively managed portfolio, trading at a 24% discount to NAV. Federal Realty Investment Trust has a 57-year dividend growth streak, high-quality retail assets, and a 4.8% yield, trading well below historical valuation norms.
Is the Options Market Predicting a Spike in Crescent Capital BDC (CCAP) Stock?
Investors need to pay close attention to Crescent Capital BDC (CCAP) stock based on the movements in the options market lately.
Bargain Alert: I'm Buying These 7-11% Yields For Recurring Income
Market volatility underscores the need for income-producing assets; Crescent Capital BDC and Omega Healthcare Investors offer compelling value with strong fundamentals and attractive yields. Crescent Capital BDC carries a diversified portfolio, high-quality secured debt, robust liquidity, and an 11% dividend yield while trading at a 15% discount to NAV. Omega Healthcare Investors benefits from a stable triple-net lease model, improving operator fundamentals, and a 7.3% dividend yield, with potential for capital appreciation.
I'm Buying Magnificent Dividends Up To 9% Yield
A contrarian mindset can help dividend investors find bargains, with Crescent Capital BDC and Cenovus Energy offering high yields after recent price drops. Crescent Capital BDC carries a diversified debt portfolio, strong dividend coverage, and a safe leverage profile, making it a compelling buy at a 9% discount to book value. Cenovus Energy's integrated operations and cost optimization efforts position it for long-term growth, with plans to return 100% of excess free cash flow to shareholders.
Crescent Capital BDC, Inc. (CCAP) Q4 2024 Earnings Conference Call Transcript
Crescent Capital BDC, Inc. (NASDAQ:CCAP ) Q4 2024 Earnings Conference Call February 20, 2025 ET Company Participants Dan McMahon - Head, IR Jason Breaux - CEO Henry Chung - President Gerhard Lombard - CFO Conference Call Participants Robert Dodd - Raymond James Mickey Schleien - Ladenburg Paul Johnson - KBW Operator Thank you for standing by. My name is Janine, and I will be your lead operator for today's call.
Crescent Capital BDC (CCAP) Q4 Earnings and Revenues Lag Estimates
Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.61 per share a year ago.
Crescent Capital BDC (CCAP) Expected to Beat Earnings Estimates: Should You Buy?
Crescent Capital BDC (CCAP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Crescent Capital BDC (CCAP) is Poised to Beat Earnings Estimates Again
Crescent Capital BDC (CCAP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
